Dual‑Agonist Metabolic Peptide for Foundational Appetite Control & Enhanced Glycemic Balance

GLP‑1 & GIP 10 mg (VioGen) delivers a balanced dual‑agonist formulation inspired by the mechanism behind Tirzepatide. This entry‑strength dose activates both GLP‑1 and GIP receptors, supporting smoother appetite control, improved metabolic efficiency, and early‑stage fat‑loss progression.

The 10 mg strength is ideal for users beginning dual‑agonist therapy or transitioning from GLP‑1‑only peptides, offering clean tolerability, stable metabolic activation, and predictable weekly progression.

Key Features

• Balanced 10 mg dual‑agonist formulation
• Activates GLP‑1 + GIP metabolic pathways
• Supports appetite suppression and craving reduction
• Enhances insulin sensitivity and glycemic stability
• Promotes early‑stage fat‑loss progression
• Smooth tolerability for beginners
• Once‑weekly injectable format
• Premium VioGen formulation with high purity

How GLP‑1 & GIP 10 mg Works

GLP‑1 Activation

• Reduces appetite
• Slows gastric emptying
• Enhances satiety

GIP Activation

• Improves insulin response
• Supports metabolic balance
• Enhances tolerability at lower doses

Together, these pathways create a synergistic metabolic effect, delivering stronger results than GLP‑1‑only peptides while maintaining a gentle, beginner‑friendly profile.

Benefits: GLP‑1 & GIP 10mg

• Strong appetite and craving control
• Improved glycemic balance
• Increased metabolic efficiency
• Early‑stage fat‑loss support
• Ideal for dose‑escalation protocols
• Once‑weekly convenience

Who It’s For

GLP‑1 & GIP 10 mg (VioGen) is suited for:

• First‑time dual‑agonist users
• Individuals transitioning from GLP‑1‑only peptides
• Users requiring a gentle but effective starting dose
• Those preparing to escalate to 20–30–50 mg strengths

• Safety Information

  Commonly reported effects:

  • Mild nausea
  • GI discomfort
  • Fatigue

  Not suitable for:

  • Pregnant or breastfeeding individuals
  • Patients with personal/family history of medullary thyroid carcinoma
  • Individuals with MEN2 syndrome

  This product is not an approved pharmaceutical and is intended for research or professional use,